# Phase II CT-2103/Carboplatin in Ovarian Cancer

> **NCT00069901** · PHASE2 · COMPLETED · sponsor: **CTI BioPharma** · enrollment: 82 (actual)

## Conditions studied

- Ovarian Neoplasm

## Interventions

- **DRUG:** CT-2103 (poly(L)glutamate-paclitaxel)
- **DRUG:** carboplatin

## Key facts

- **NCT ID:** NCT00069901
- **Lead sponsor:** CTI BioPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-02
- **Primary completion:** 2005-11
- **Final completion:** 2006-09
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2008-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00069901

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00069901, "Phase II CT-2103/Carboplatin in Ovarian Cancer". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT00069901. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*